Method for predicting efficacy of anti-PD-1 antibody or anti-PD-L1 antibody therapy, method for evaluating cancer grade, and method for enhancing efficacy of anti-PD-1 antibody or anti-PD-L1 antibody therapy
US-11899019-B2 · Feb 13, 2024 · US
This page is not indexed by search engines while we improve data quality.
Endou Hitoshi patents
Endou Hitoshi is listed as an inventor on 7 patents in our database. Major assignees and classification codes are summarized below.
| Metric | Value |
|---|---|
| Inventor | Endou Hitoshi |
| Total patents | 7 |
| First publication | Jun 9, 2015 |
| Latest publication | Feb 13, 2024 |
Notable patents
Publications ranked by popularity score, then publication date.
Method for predicting efficacy of anti-pd-1 antibody or anti-pd-l1 antibody therapy, method for evaluating cancer grade, and method for enhancing efficacy of anti-pd-1 antibody or anti-pd-l1 antibody therapy
US-2021148920-A1 · May 20, 2021 · US
URAT1 inhibitor
US-10173990-B2 · Jan 8, 2019 · US
Urat1 inhibitor
US-2017290795-A1 · Oct 12, 2017 · US
Anti-CD98 antibody processes
US-9688770-B2 · Jun 27, 2017 · US
Anti-cd98 antibody processes
US-2015307621-A1 · Oct 29, 2015 · US
Anti-CD98 antibody processes
US-9051374-B2 · Jun 9, 2015 · US
Recent patents
Latest publications not already listed above.
No data yet.
Major assignees
Companies most often associated with this inventor's publications.
| Assignee | Patents |
|---|---|
| Kyowa Hakko Kirin Co Ltd | 4 |
| J Pharma Co Ltd | 3 |
| Nippon Chemiphar Co | 2 |
| Dethree Res Lab Inc | 2 |
| Univ Gunma Nat Univ Corp | 2 |
Top CPC classifications
Most common classification codes across this inventor's patents.
| CPC | Patents |
|---|---|
| A61P35/00 | 5 |
| A61K2039/505 | 5 |
| A61K31/423 | 4 |
| C07K2317/30 | 3 |
| C07K2317/565 | 3 |